Latest Perspectives in PAD: How to Improve Outcomes

Slides:

Advertisements

Similar presentations

Dharam J. Kumbhani, MD, SM, MRCP, Ph. Gabriel Steg, MD, Christopher P. Cannon, MD, Kim A Eagle, MD, Sidney C. Smith, Jr., MD, Shinya Goto, MD, Cannon,

Advertisements

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.

Limbs International Medical Buflomedil Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Alain Leizorovicz LIMB.

1 HOT LINE PRESENTATION World Congress of Cardiology 2006 Barcelona, Spain September 5, 2006 Warfarin Antiplatelet Vascular Evaluation PAD Patients.

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise,

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease Debbie C. Chen1, Gagan.

Rivaroxaban in stable peripheral or carotid artery disease

Management of mitral regurgitation. See legend for Fig

Rivaroxaban in stable peripheral or carotid artery disease

LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice.

Preventing Thrombotic Complications in ACS: State of the Art

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Medical Therapy for Peripheral Artery Disease

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Bleeding and cancer risk in patients with vascular disease COMPASS Steering Committee and Investigators.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

A CASE CHALLENGE IN HFrEF:

PAD Patients vs Post-ACS Patients:

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

SGLT2 Inhibitors and CV Outcomes

Antiplatelet Therapy and Secondary Prevention

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

PCSK9 Inhibitors and Cardiovascular Outcomes

Understanding PAD.

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

Risk Stratification in CAD and PAD

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial Kelley Branch,

CV Risk Doesn't End in the Cath Lab

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.

Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

Antithrombotic Therapy in PAD

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

Contemporary Evidence-Based Guidelines

How to Optimize Cholesterol Management in High-Risk CV Patients

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Factor Xa Inhibitors in Coronary Artery Disease

Improving Adherence to Antiplatelet Therapy After an ACS Event

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Nat. Rev. Cardiol. doi: /nrcardio

Reassessing Risk Stratification in CAD/PAD

PCSK9 Inhibitors and Real-World Evidence

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

Latest Perspectives in PAD: How to Improve Outcomes

PAD: A Global Burden

PAD: A Generalized Process

PAD: Definitions

Risk Factors for PAD

Diagnosis: Ankle Brachial Index

CONTENT NO LONGER AVAILABLE http://www.heart.org/idc/groups/heart-public/@wcm/@hcm/documents/downloadable/ucm_491938.pdf Reproduced with permission. AHA website.

PAD: Treatment

AHA/ACC Guidelines: Antiplatelet Agents

EUCLID: Primary Efficacy Endpoint

Latest Perspectives in PAD: How to Improve Outcomes?

COMPASS: CAD and PAD Groups

COMPASS: PAD Subgroup

COMPASS: PAD Subgroup (cont)

COMPASS: Incidence of Death Before and After MALE CONTENT NO LONGER AVAILABLE doi: 10.1016/j.jacc.2018.03.008. [Epub ahead of print] Rate are /100 pt-years Reprinted from J Am Coll Cardiol, pii: S0735-1097(18)33502-2, Anand SS, Caron F, Eikelboom JW, et al, Major adverse limb events in lower extremity peripheral artery disease: COMPASS trial, Copyright 2018, with permission from Elsevier.

COMPASS: Incidence of Amputation Before and After MALE CONTENT NO LONGER AVAILABLE doi: 10.1016/j.jacc.2018.03.008. [Epub ahead of print] Reprinted from J Am Coll Cardiol, pii: S0735-1097(18)33502-2, Anand SS, Caron F, Eikelboom JW, et al, Major adverse limb events in lower extremity peripheral artery disease: COMPASS trial, Copyright 2018, with permission from Elsevier.

COMPASS: Prognosis After MALE by Treatment Group

COMPASS: Patients With MALE Index Event CONTENT NO LONGER AVAILABLE doi: 10.1016/j.jacc.2018.03.008. Cox proportional hazards models with the MALE index event modelled as a time-dependent covariate *considering only those outcomes that did not occur on the same day as the index MALE Reprinted from J Am Coll Cardiol, pii: S0735-1097(18)33502-2, Anand SS, Caron F, Eikelboom JW, et al, Major adverse limb events in lower extremity peripheral artery disease: COMPASS trial, Copyright 2018, with permission from Elsevier.

VOYAGER PAD: Study Design

Latest Perspectives in PAD: How to Improve Outcomes

Overview

PAD: A Polyvascular Disease

PAD: Increased Risk for MACE

AHA/ACC Guidelines: Antiplatelet Agents

PLATO and PEGASUS: PAD Subanalysis

EUCLID: Primary Efficacy Endpoint

Anticoagulation in PAD: WAVE

Latest Perspectives in PAD: How to Improve Outcomes

Lower Extremity Artery Disease: "LEAD"

ESC Guidelines

Measuring ABI

Therapeutic Approach to PAD

Limitations of Treatment

ESC Guidelines: Antiplatelet Therapy

COMPASS

Summary

Summary (cont)

Abbreviations

Abbreviations (cont)